Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
HEIDELBERG, Germany, Oct. 26, 2016 -- Affimed N.V. (Nasdaq:AFMD) today announced that on November 2, 2016, the Company will release its financial results for the quarter ended September 30, 2016. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Wednesday, November 2, 2016 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 7663835.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 716 8256 |
| Local - Copenhagen, Denmark: | +4532 71 16 59 |
| Local – Frankfurt, Germany: | +49 (0) 69 2222 10630 |
| Local - Geneva, Switzerland: | +41 (0) 22 417 7109 |
| Local - London, U.K.: | +44 (0) 20 3140 8286 |
| Local - New York City, U.S.A.: | +1 646 254 3362 |
| Local - Paris, France: | +33 (0) 1 76 77 22 22 |
An audio webcast of the conference call can be accessed in the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: [email protected] or [email protected] Media Contact: Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: [email protected]
